Overview
IN8bio Q3 net loss narrows to $3.9 mln from $7.1 mln last year
R&D expenses for Q3 decreased due to strategic pause in INB-400 program
Company expanded INB-100 trial to accelerate enrollment at multiple sites
Outlook
IN8bio to present updated INB-200/400 data at SNO Annual Meeting, Nov 19-23, 2025
Additional INB-619 preclinical data to be presented at ASH Annual Meeting, Dec 6-9, 2025
Result Drivers
R&D EXPENSES - Expenses fell to $2.1 mln from $3.3 mln due to pause on clinical trial-related activities for the INB-400 program last year and personnel-related costs
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Net Income | -$3.85 mln | ||
Q3 Basic EPS | -$0.85 | ||
Q3 Operating Expenses | $3.97 mln | ||
Q3 Operating Income | -$3.85 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
Wall Street's median 12-month price target for IN8bio Inc is $7.00, about 76.7% above its November 5 closing price of $1.63
Press Release: ID:nGNX1KqHtc
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)